drugset / Trial / NCT01755468
Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Pilot Study)
Phase 3
Completed
24 enrolled
Mount Sinai Hospital, Canada
Canadian Institutes of Health Research (CIHR) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Type 2 diabetes mellitus is a chronic metabolic disorder characterized by progressive deterioration in the function of the pancreatic beta-cells, which are the cells that produce and secrete insulin (the hormone primarily responsible for the handling of glucose in the body). The investigators propose a pilot randomized controlled trial to determine whether intermittent intensive insulin therapy is an effective therapeutic strategy that can preserve pancreatic beta-cell function and maintain glycemic control early in the course of type 2 diabetes.
Timeline
- Start
- 2013-04
- Primary completion
- 2017-10
- Completion
- 2017-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Insulin Lispro | Protein / enzyme biologic | — | — |
| Comparator | Metformin | Small molecule | 1000 mg | — |
| Subject | insulin glargine | Protein / enzyme biologic | — | — |